SMNdelta7 SMA mouse model: single IV clinical vector lots gave dose-dependent survival improvement
“At dose levels of 1.2 x 1013 up to 1.1 x 1014 vg/kg, the single IV administration of the various clinical vector lots of AVXS-101 resulted in a dose-dependent improvement in survival in neonatal SMNdelta7 mice.”
✓ VerifiedFDA pharmacology/toxicology review, p. 13Source ↗
Why that model
Not stated in public reviews
Not reported in the public reviews. Reviewers summarise selectively, so this usually means it wasn't discussed publicly, not that it wasn't studied.
Reviewer's view of the efficacy data
Small therapeutic window in mice; no clear justification for clinical dose selection as underlying data missing
“Ultimately, the therapeutic window in mice is small and there is no clear rationale or justification for clinical dose selection, since underlying data are missing.”
WAS-deficient mice transplanted with WAS LVV-transduced murine Lin- BM cells: increased B cells, platelets, granulocytes; improved T, B and DC function